← Search & browse all drugs

other meningococcal polyvalent purified polysaccharides antigen

J07AH05

Forms & Strengths

Lyophilized powder for injection
Liquid suspension for injection
4-valent (A, C, W-135, Y) vaccine
Conjugate and polysaccharide formulations available

Adult Dosing

0.5 mL dose, intramuscularly
Single dose for individuals 55 years and older
Booster doses may be indicated for certain individuals
Dosing interval varies based on vaccine formulation and patient risk factors

Pediatric Dosing

0.5 mL dose, intramuscularly
First dose at 2 months of age, with subsequent doses at 4, 6, and 12-15 months
Catch-up vaccination recommended for children who start the series late
Formulations specifically designed for pediatric use

Indications

Prevention of invasive meningococcal disease caused by serogroups A, C, W-135, and Y
High-risk individuals, such as those with complement deficiencies or asplenia
Outbreak response and control
Travelers to areas with high incidence of meningococcal disease

Mechanism of Action

Induces immunity against meningococcal serogroups A, C, W-135, and Y
Stimulates production of protective antibodies
Enhances phagocytosis and killing of meningococcal bacteria

Contraindications

Severe allergic reaction to vaccine components or previous dose
Pregnancy, although vaccination may be recommended in certain situations
Moderate to severe acute illness, until condition improves

Adverse Reactions

Pain, redness, or swelling at injection site
Fatigue, headache, or malaise
Fever, chills, or muscle aches
Less common: anaphylaxis, rash, or other hypersensitivity reactions

Drug Interactions

Administer simultaneously with other vaccines, at different injection sites
Use with caution in patients receiving immunosuppressive therapy
Potential for reduced immune response when co-administered with other vaccines

Curated Content: Needs Vetting Before Put to Clinical Use